Earnings call transcript: Navamedic Q4 2026 sees revenue miss, stock dips

Navamedic/Nava reported a 14.35% revenue miss for Q4 2026, with stock down 8.33% after the announcement. Standalone PAT surged 116% to INR 911 crore and the company declared its highest-ever dividend at INR 8.55 per share, but consolidated results were weighed by non-cash deferred tax adjustments tied to Zambian kwacha appreciation. Management guided FY2027 EPS to $0.41 and outlined continued investment in solar and agro projects, while saying power and ferroalloy volumes should be broadly stable with EBITDA margins around 35%-40%.

Analysis

The market is likely keying on the gap between headline cash-generation and the deterioration in the near-term earnings bridge. This is a classic “good balance sheet, bad optics” setup: deferred tax noise is non-cash, but the underlying issue is that FX volatility is now leaking into reported profitability just as the company is asking investors to underwrite multiple growth projects. That combination usually compresses the multiple first and only later rewards the stock if execution proves out.

Second-order, the business is becoming more capital-allocation sensitive than operating-sensitive. Management is effectively telling you the equity story is no longer just about legacy assets; the portfolio now depends on a sequence of project milestones, tariff realization, and commodity/FX offsets lining up over the next 6-18 months. That increases the penalty for delays because the market will start capitalizing the funding overhang before the new assets contribute meaningfully.

The contrarian angle is that the selloff may be overdone if investors are conflating accounting FX with cash erosion. If the company can keep collections tight, fund capex without stressing the balance sheet, and preserve power/coal economics, then reported tax volatility should fade while new capacity starts to de-risk the growth narrative. The key question is whether the next two quarters show enough operational follow-through to offset the multiple reset from this miss.

I would watch for three catalysts: reversal in reported tax drag, evidence that the new solar/power economics flow through to margin, and any acceleration in project commissioning. If those arrive together, this becomes a re-rating candidate; if not, the current setup likely stays in a “cheap for a reason” purgatory for several quarters.

Key Decisions for Investors

• Avoid initiating fresh long exposure into the next earnings print; wait 1-2 quarters for proof that reported tax volatility is stabilizing before paying up for growth optionality.
• For existing holders, consider a collar: hold the core position but buy downside protection 3-6 months out while funding it by selling modest upside, since the stock is likely to trade on headlines around FX and project timing rather than fundamentals.
• Pair trade idea: long a cash-generative utility/industrial with clean reported earnings against short this name if you want to express the view that accounting noise will keep this multiple capped over the next 1-2 quarters.
• If the stock drops another 8-12% on no-new-information weakness, look for a tactical rebound trade only if management confirms project commissioning dates and no deterioration in collections/liquidity.